Elevated soluble ADAM8 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia

Osamu Matsuno1, Eishi Miyazaki, Shinichi Nureki

  • 1Division of Respiratory Disease, Department of Brain and Nerve Science, Oita University Faculty of Medicine, Yufu City, Oita, Japan. matsuno@med.oita-u.ac.jp

Abstract

Insights

ADAM8 is linked to eosinophilic lung inflammation. Elevated ADAM8 levels correlate with specific eosinophilic pneumonia types, suggesting its role in human allergic responses.

Area of Science:

  • Immunology
  • Biochemistry
  • Pulmonology

Background:

  • ADAM (a disintegrin and metalloprotease) proteins are key in proteolysis and cell adhesion.
  • ADAM8, a specific member, is implicated in allergic inflammation and acts as a sheddase for VCAM-1 and CD23.
  • VCAM-1 and CD23 are crucial in immune cell trafficking and allergic responses.

Purpose of the Study:

  • To investigate the role of ADAM8 in the pathogenesis of eosinophilic pneumonia (EP).
  • To quantify soluble ADAM8 (sADAM8) and its substrates (sVCAM-1, sCD23) in different EP subtypes.
  • To establish correlations between sADAM8, sVCAM-1, and sCD23 levels in EP.

Main Methods:

  • Measurement of sADAM8, sVCAM-1, and sCD23 in bronchoalveolar lavage fluid.
  • Analysis of patient samples from acute eosinophilic pneumonia (AEP), chronic idiopathic eosinophilic pneumonia (CEP), and drug-induced eosinophilic pneumonia (drug-EP).
  • Statistical correlation analysis between measured biomarker concentrations.

Main Results:

  • Increased concentrations of sADAM8 and sVCAM-1 were observed in both AEP and CEP.
  • Elevated sCD23 levels were specifically found in AEP.
  • A significant positive correlation between sADAM8 and both sVCAM-1 and sCD23 was identified in AEP, but not in CEP.

Conclusions:

  • The distinct patterns of ADAM8 involvement highlight differing pathogenetic mechanisms across EP subtypes.
  • These findings represent the first evidence linking ADAM8 to human eosinophilic responses and lung inflammation.
  • ADAM8 emerges as a potential biomarker and therapeutic target in specific forms of eosinophilic lung disease.